Migraine Drugs

Global Market Trajectory & Analytics

MCP-6126

EXECUTIVE ENGAGEMENTS

POOL

10594
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1271
Interactions with Platform & by Email

PARTICIPANTS

318
Unique # Participated

VALIDATIONS

78
Responses Validated*

COMPANIES

59
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

306

PAGES

395

EDITION

18

PRICE

USD 5450

CODE

MCP-6126


COMPETITIVE METRICS

COMPANY

D S N T

% *

Astellas Pharma US, Inc.

Login Required

Astellas Pharma, Inc.

Login Required

Astrazeneca Pharmaceuticals LP

Login Required

AstraZeneca PLC

Login Required

Aurobindo Pharma Ltd.

Login Required

Bayer AG

Login Required

BioTrak Therapeutics

Login Required

Boehringer Ingelheim International GmbH

Login Required

Bristol-Myers Squibb Company

Login Required

Dr. Reddy`s Laboratories Ltd.

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial
* Validated respondents are incentivized with cluster data
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 59 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Migraine Drugs estimated at US$2.3 Trillion in the year 2020, is projected to reach a revised size of US$6.9 Trillion by 2027, growing at aCAGR of 16.9% over the period 2020-2027. Acute Treatment, one of the segments analyzed in the report, is projected to record 17.5% CAGR and reach US$5.4 Trillion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Preventive Treatment segment is readjusted to a revised 15.1% CAGR for the next 7-year period.
The Migraine Drugs market in the U.S. is estimated at US$620.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Trillion by the year 2027 trailing a CAGR of 21.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.1% and 15% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.4% CAGR.

SELECT PLAYERS

Allergan PLC; Amgen, Inc.; Biohaven Pharmaceutical Holding Company Ltd.; Eli Lilly and Company; GlaxoSmithKline PLC; Johnson & Johnson; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.

SEGMENTS

» Treatment (Acute Treatment, and Preventive Treatment) » Therapeutic Class (Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs, and Other Therapeutic Classes) » Route of Administration (Oral, Injectables, and Other Route of Administrations)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Migraine Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
World Current & Future Analysis for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Acute Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Acute Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Preventive Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Preventive Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Triptans by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Triptans by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Triptans by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Acetylcholine Inhibitors/Neurotoxins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Acetylcholine Inhibitors/Neurotoxins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Acetylcholine Inhibitors/Neurotoxins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Ergot Alkaloids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Ergot Alkaloids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Ergot Alkaloids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
World Current & Future Analysis for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Route of Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Route of Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
USA Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
CANADA
Canada Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Canada Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
JAPAN
Japan Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Japan Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
CHINA
China Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
China Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
China Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
EUROPE
Europe Current & Future Analysis for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Migraine Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
Europe Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Europe Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
France Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
France Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
GERMANY
Germany Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Germany Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
ITALY
Italy Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Italy Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
UNITED KINGDOM
UK Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
UK Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
SPAIN
Spain Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Spain Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Spain Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Spain Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Spain 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
RUSSIA
Russia Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Russia Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Russia Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Russia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Russia 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
REST OF EUROPE
Rest of Europe Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Rest of Europe Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Migraine Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Asia-Pacific Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
AUSTRALIA
Australia Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Australia Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Australia Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Australia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Australia 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
INDIA
India Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
India Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
India Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
India Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
India 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
SOUTH KOREA
South Korea Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
South Korea Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
South Korea Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
South Korea Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
South Korea 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
REST OF ASIA-PACIFIC
Rest of Asia-Pacific Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Rest of Asia-Pacific Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Asia-Pacific Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Asia-Pacific 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
LATIN AMERICA
Latin America Current & Future Analysis for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Latin America Historic Review for Migraine Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Latin America Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Latin America Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Latin America 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
ARGENTINA
Argentina Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Argentina Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Argentina Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Argentina Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Argentina 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
BRAZIL
Brazil Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Brazil Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Brazil Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Brazil Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Brazil 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
MEXICO
Mexico Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Mexico Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Mexico Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Mexico Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Mexico 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
REST OF LATIN AMERICA
Rest of Latin America Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Rest of Latin America Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Rest of Latin America Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Latin America Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Latin America 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
MIDDLE EAST
Middle East Current & Future Analysis for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Middle East Historic Review for Migraine Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Migraine Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Middle East Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Middle East Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Middle East 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
IRAN
Iran Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Iran Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Iran Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Iran Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Iran 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
ISRAEL
Israel Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Israel Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Israel Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Israel Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Israel 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
SAUDI ARABIA
Saudi Arabia Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Saudi Arabia Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Saudi Arabia Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Saudi Arabia Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Saudi Arabia 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
UNITED ARAB EMIRATES
UAE Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
UAE Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
UAE Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UAE Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UAE 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
REST OF MIDDLE EAST
Rest of Middle East Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Rest of Middle East Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Rest of Middle East Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Middle East Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Middle East 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
AFRICA
Africa Current & Future Analysis for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Migraine Drugs by Treatment - Acute Treatment and Preventive Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Migraine Drugs by Treatment - Percentage Breakdown of Value Sales for Acute Treatment and Preventive Treatment for the Years 2012, 2020 & 2027
Africa Current & Future Analysis for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Migraine Drugs by Therapeutic Class - Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Migraine Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Triptans, Acetylcholine Inhibitors/Neurotoxins, Ergot Alkaloids, NSAIDs and Other Therapeutic Classes for the Years 2012, 2020 & 2027
Africa Current & Future Analysis for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Africa Historic Review for Migraine Drugs by Route Of Administration - Oral, Injectables and Other Route of Administrations Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Africa 15-Year Perspective for Migraine Drugs by Route Of Administration - Percentage Breakdown of Value Sales for Oral, Injectables and Other Route of Administrations for the Years 2012, 2020 & 2027
Total Companies Profiled: 59

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com